



Alexandra U Scherrer

Contact

Alexandra U Scherrer

Publications (27)

Kusejko K, Smith D, Scherrer A, Paioni P, Kohns Vasconcelos M, Aebi-Popp K, Kouyos R, Günthard H, Kahlert C, Swiss HIV Cohort Study and the Swiss Mother and Child HIV Cohort Study. Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study. *JMIR Form Res* 2023; 7:e44567.

Jakeman B, Scherrer A, Darling K, Damas J, Bieler-Aeschlimann M, Hasse B, Schlosser L, Hachfeld A, Gutbrod K, Tarr P, Calmy A, Assal F, Kunze U, Stoeckle M, Schmid P, Rossi S, Di Benedetto C, Du Pasquier R, Cavassini M, Marzolini C, Hundsberger T. Anticholinergic and Sedative Medications Are Associated With Neurocognitive Performance of Well Treated People With Human Immunodeficiency Virus. *Open Forum Infect Dis* 2022; 9:ofac457.

Balakrishna S, Günthard H, Battegay M, Bernasconi E, Schmid P, Cavassini M, Calmy A, Hauser C, Furrer H, Scherrer A, Kusejko K, Roth J, Kachalov V, Wolfensberger A, Kouyos R. Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study. *J Infect Dis* 2021

Scherrer A, Wandeler G, Fellay J, Bucher H, Yerly S, Suter F, Hirsch H, Huber M, Dollenmaier G, Perreau M, Martinetti G, Rauch A, Günthard H, Marzolini C, Tarr P, Traytel A, Braun D, Calmy A, Battegay M, Cavassini M, Furrer H, Schmid P, Bernasconi E, Stoeckle M, Kahlert C, Trkola A, Kouyos R, Swiss HIV Cohort Study (SHCS). Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). *Int J Epidemiol* 2021

Pyngottu A, Günthard H, Bernasconi E, Vernazza P, Furrer H, Stöckle M, Cavassini M, Calmy A, Yerly S, Perreau M, Hirsch H, Huber M, Kouyos R, Scherrer A, Swiss HIV Cohort Study. Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment. *Clin Infect Dis* 2020

Roth J, Bogojeska J, Bernasconi E, Kahlert C, Cavassini M, Calmy A, Scherrer A, Fux C, Kouyos R, Günthard H, Rauch A, Marzolini C, Radevski G, Battegay M. Cohort-derived machine learning models for individual prediction of chronic kidney disease in people living with HIV: a prospective multicentre cohort study. *J Infect Dis* 2020

Abela I, Günthard H, Bernasconi E, Cavassini M, Schmid P, Calmy A, Furrer H, Hirsch H, Perreau M, Klimkait T, Yerly S, Böni J, Scherrer A, Swiss HIV Cohort Study. Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. *Clin Infect Dis* 2020; 70:297-303.

Young J, Bucher H, Günthard H, Vernazza P, Hachfeld A, Cavassini M, Bernasconi E, Tarr P, Calmy A, Scherrer A, Swiss HIV Cohort Study. The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. *Antivir Ther (Lond)* 2019

Kouyos R, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Metzner K, Günthard H, Trkola A, Chave J, Kuster H, Leemann C, Rusert P, Kadelka C, Huber M, Marzel A, Ebner H, Schanz M, Liechti T, Friedrich N, Braun D, Scherrer A, Weber J, Uhr T, Baumann N, Swiss HIV Cohort Study. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. *Nature* 2018; 561:406-410.

Strouvelle V, Günthard H, Metzner K, Hoffmann M, Darling K, Rauch A, Stöckle M, Kouyos R, Kok Y, Scherrer A, Vongrad V, Braun D, Zurich Primary HIV Infection Study and the Swiss HIV Cohort Study. No Effect of Pegylated Interferon- α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. *J Infect Dis* 2018; 217:1883-1888.

Kadelka C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Kouyos R, Günthard H, Trkola A, Cavassini M, Misselwitz B, Liechti T, Ebner H, Schanz M, Rusert P, Friedrich N, Stiegeler E, Braun D, Huber M, Scherrer A, Weber J, Uhr T, Kuster H, Swiss HIV Cohort Study. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. *J Exp Med* 2018; 215:1589-1608.

Bertels F, Cavassini M, Calmy A, Bernasconi E, Schmid P, Scherrer A, Müller V, Bonhoeffer S, Kouyos R, Regoes R, Rauch A, Battegay M, Marzel A, Leventhal G, Mitov V, Fellay J, Günthard H, Böni J, Yerly S, Klimkait T, Aubert V, Swiss HIV Cohort Study. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. *Mol Biol Evol* 2018; 35:27-37.

Combes J, Scherrer A, Waterboer T, Franceschi S, Günthard H, Bernasconi E, Schmid P, Calmy A, Hauser C, Hirsch H, Cavassini M, Egger M, Clifford G, Swiss HIV Cohort Study. Human papillomavirus antibody response following HAART initiation among MSM. *AIDS* 2017; 31:561-569.

Shilaih M, Kouyos R, Günthard H, Thurnheer M, Bernasconi E, Hoffmann M, Battegay M, Darling K, Calmy A, Young J, Kovari H, Scherrer A, Braun D, Marzel A. Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. *Medicine (Baltimore)* 2017; 96:e5849.

Shilaih M, Kouyos R, Günthard H, Furrer H, Bernasconi E, Vernazza P, Klimkait T, Cavassini M, Aubert V, Hirsch H, Yerly S, Böni J, Schüpbach J, Scherrer A, Yang W, Marzel A, Swiss HIV Cohort Study. Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. *Sci Rep* 2016; 6:27580.

Shilaih M, Kouyos R, Günthard H, Hirzel C, Bernasconi E, Hoffmann M, Battegay M, Darling K, Rougemont M, Kovari H, Braun D, Scherrer A, Marzel A. Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. *J Infect Dis* 2016; 214:599-606.

Scherrer A, Günthard H, Bernasconi E, Schmid P, Calmy A, Hauser C, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W. Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. *J Infect Dis* 2016; 214:399-402.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Calmy A, Furrer H, Battegay M, Cavassini M, Aubert V, Klimkait T, Yerly S, Böni J, Kouyos R, Yang W, von Wyl V. Emergence of acquired HIV-1 drug resistance has almost been stopped in Switzerland - a 15 year prospective cohort analysis. *Clin Infect Dis* 2016

Yang W, Swiss HIV Cohort Study (SHCS), Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Hirzel C, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study SHCS. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. *J Antimicrob Chemother* 2015

Yang W, Günthard H, Ledergerber B, Held L, Vernazza P, Bernasconi E, Cavassini M, Battegay M, Furrer H, Aubert V, Klimkait T, Yerly S, Shah C, Böni J, Scherrer A, Kouyos R, Swiss HIV Cohort Study. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. *J Infect Dis* 2015

Metzner K, Günthard H, Weber R, Bernasconi E, Calmy A, Cavassini M, Vernazza P, Hirsch H, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, von Wyl V, Scherrer A, the Swiss HIV Cohort Study. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. *AIDS* 2014; 28:2231-2239.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, the Swiss HIV Cohort Study (SHCS). Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. *PLoS one* 2013; 8

Metzner K, Aubert V, Furrer H, Battegay M, Vernazza P, Cavassini M, Calmy A, Bernasconi E, Weber R, Günthard H, Klimkait T, Yerly S, Böni J, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C, Rieder P, Braun D, Grube C, Kuster H, Swiss HIV Cohort Study. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. *J Infect Dis* 2013; 208:1102-12.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Aubert V, Klimkait T, Yerly S, Böni J, Swiss HIV Cohort Study (SHCS). Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. *PloS one* 2012; 7:e50307.

Scherrer A, Günthard H, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Calmy A, Furrer H, Cellera C, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients. *PloS one* 2012; 7:e37983.

Scherrer A, Günthard H, Held L, Bernasconi E, Vernazza P, Elzi L, Cavassini M, Hirschel B, Rauch A, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Ledergerber B, Swiss HIV Cohort Study. Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. *Clin Infect Dis* 2011; 53:1143-52.

Scherrer A, Günthard H, Ledergerber B, Bernasconi E, Vernazza P, Battegay M, Cavassini M, Hirschel B, Garzoni C, Bürgisser P, Klimkait T, Yerly S, Böni J, von Wyl V, Swiss HIV Cohort Study (SHCS). Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors. *J Acquir Immune Defic Syndr* 2011; 57:24-31.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch